GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » EV-to-FCF

DexTech Medical AB (XSAT:DEX) EV-to-FCF : -85.94 (As of Jun. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DexTech Medical AB's Enterprise Value is kr52.85 Mil. DexTech Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.62 Mil. Therefore, DexTech Medical AB's EV-to-FCF for today is -85.94.

The historical rank and industry rank for DexTech Medical AB's EV-to-FCF or its related term are showing as below:

XSAT:DEX' s EV-to-FCF Range Over the Past 10 Years
Min: -1583.83   Med: -380.17   Max: 5022.9
Current: -88.94

During the past 11 years, the highest EV-to-FCF of DexTech Medical AB was 5022.90. The lowest was -1583.83. And the median was -380.17.

XSAT:DEX's EV-to-FCF is ranked worse than
100% of 397 companies
in the Biotechnology industry
Industry Median: 6.42 vs XSAT:DEX: -88.94

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-21), DexTech Medical AB's stock price is kr4.00. DexTech Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.250. Therefore, DexTech Medical AB's PE Ratio for today is At Loss.


DexTech Medical AB EV-to-FCF Historical Data

The historical data trend for DexTech Medical AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB EV-to-FCF Chart

DexTech Medical AB Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -292.28 -253.77 -199.14 -10.48 -5.65

DexTech Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.92 -5.65 -66.45 -53.10 -144.85

Competitive Comparison of DexTech Medical AB's EV-to-FCF

For the Biotechnology subindustry, DexTech Medical AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's EV-to-FCF falls into.



DexTech Medical AB EV-to-FCF Calculation

DexTech Medical AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=52.852/-0.615
=-85.94

DexTech Medical AB's current Enterprise Value is kr52.85 Mil.
DexTech Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexTech Medical AB  (XSAT:DEX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

DexTech Medical AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.00/-0.250
=At Loss

DexTech Medical AB's share price for today is kr4.00.
DexTech Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


DexTech Medical AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB (XSAT:DEX) Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a strong clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.